Arcus Biosciences (RCUS) EPS (Weighted Average and Diluted) (2019 - 2026)
Arcus Biosciences (RCUS) recorded quarterly EPS (Weighted Average and Diluted) of -$1.02 in Q1 2026, down 13.33% quarter-over-quarter from -$0.9 in Q4 2025, and up 10.53% on a YoY basis from -$0.92 in Q1 2025.
Arcus Biosciences (RCUS) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Arcus Biosciences' EPS (Weighted Average and Diluted) history runs 8 years deep, the most recent figure standing at -$1.02 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 10.53% year-over-year to -$1.02; the TTM figure through Mar 2026 stood at -$3.19 (up 23.87% YoY), while the FY2025 annual figure was -$3.29, down 4.78% from the prior year.
- EPS (Weighted Average and Diluted) was -$1.02 for Q1 2026 at Arcus Biosciences, down from -$0.9 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.05 in Q1 2024 to a low of -$1.27 in Q3 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.96 across 5 years, with a median of -$1.01 in 2024.
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) jumped 95.41% in 2024, then sank 2180.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.93 in 2022, then slipped by 16.13% to -$1.08 in 2023, then gained by 4.63% to -$1.03 in 2024, then increased by 12.62% to -$0.9 in 2025, then fell by 13.33% to -$1.02 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.02 (Q1 2026), -$0.9 (Q4 2025), and -$1.27 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Arcus Biosciences | 3.05 Bn | 2.23 Bn | - | -1.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.02 |
| Dec 31, 2025 | -0.90 |
| Sep 30, 2025 | -1.27 |
| Mar 31, 2025 | -1.14 |
| Dec 31, 2024 | -1.03 |
| Sep 30, 2024 | -1.00 |
| Jun 30, 2024 | -1.02 |
| Mar 31, 2024 | -0.05 |
| Dec 31, 2023 | -1.08 |
| Sep 30, 2023 | -0.94 |
| Jun 30, 2023 | -1.04 |
| Mar 31, 2023 | -1.09 |
| Dec 31, 2022 | -0.93 |
| Sep 30, 2022 | -0.90 |
| Jun 30, 2022 | -0.93 |
| Mar 31, 2022 | -0.96 |
| Dec 31, 2021 | 3.99 |
| Sep 30, 2021 | -1.11 |
| Dec 31, 2020 | -0.87 |
| Sep 30, 2020 | 0.03 |